Video

Episode 10 - Additional Sodium Glucose Cotransporter 2 Inhibitors in the Pipeline

Two sodium glucose cotransporter 2 (SGLT-2) inhibitors (canagliflozin and dapagliflozin) have received approval from the FDA. In this segment, Peter Salgo, MD, highlights 2 additional SGLT-2 inhibitors that are currently in the drug pipeline for the treatment of type 2 diabetes mellitus (T2DM).

Jeffrey D. Dunn, PharmD, MBA; Kari Uusinarkaus, MD, FAAFP, FNLA; Dr Salgo; and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss the need for additional SGLT-2 inhibitors and consider how the availability of more treatment options will affect the costs of treating and managing T2DM.

Together, the experts conclude that as new agents continue to emerge, it will be important to assess and compare their effectiveness in specific patient populations.

Dr Handelsman adds that treatment recommendations are expected to be updated as healthcare professionals gain new insight about the use of SGLT-2 inhibitors in clinical practice.

Maria Lopes, MD, MS, hopes that as more experience is gained in matching appropriate patients to appropriate therapies, real-world use will establish the clinical value of SGLT-2 inhibitors.


Related Videos
dr jennifer green
dr jennifer green
dr ken cohen
dr ian neeland
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo